Vor Biopharma Inc (VOR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.19B
Last updated: Nov 17, 2026 at 11:05 AM ET
Vor Biopharma Inc (VOR) Competitors
The companies most similar to Vor Biopharma are Verastem (VSTM), Vir Biotechnology (VIR) and Corvus Pharmaceuticals (CRVS). By market cap, Vor Biopharma ranks 9th of the 13 companies on this page; Beam Therapeutics (BEAM) is the largest at $2.36B.
Peer Comparison
VOR's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Vor Biopharma (VOR) | $1.19B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Verastem Inc (VSTM) | $1.03B | N/A | 7.8x | -178.4% | -110.4% | 113.6% | 0.00% |
| Vir Biotechnology Inc (VIR) | $1.71B | N/A | 5.4x | -61.0% | N/A | 19582.0% | 0.00% |
| Corvus Pharmaceuticals Inc (CRVS) | $897.52M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Theravance Biopharma Inc (TBPH) | $884.18M | 95.1x | 8.4x | 51.6% | N/A | -20.9% | 0.00% |
| Nuvation Bio Inc (NUVB) | $1.41B | N/A | 6.7x | -67.4% | -18.7% | 242.6% | 0.00% |
| Tyra Biosciences Inc (TYRA) | $1.38B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Biohaven Ltd. (BHVN) | $2.09B | N/A | N/A | 0.0% | -315.9% | 0.0% | 0.00% |
| Beam Therapeutics Inc (BEAM) | $2.36B | N/A | 15.0x | -73.9% | -29.7% | -96.8% | 0.00% |
| Vera Therapeutics Inc (VERA) | $2.03B | N/A | 189.3x | 0.0% | -83.0% | 0.0% | 0.00% |
| DBV Technologies (DBVT) | $692.19M | N/A | N/A | 0.0% | -130.3% | -42.9% | 0.00% |
| Inhibrx Biosciences, Inc. (INBX) | $1.23B | N/A | 610.4x | 0.0% | -66.0% | -100.0% | 0.00% |
| Zenas BioPharma, Inc. Common Stock (ZBIO) | $1.90B | N/A | 168.0x | 0.0% | -104.3% | -100.0% | 0.00% |
| Peer median | $1.40B | 95.1x | 11.7x | 0.0% | -93.7% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Vor Biopharma, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Verastem Inc (VSTM) | Verastem, Inc., a developing-stage biopharmaceutical company focused on developing and commercializing life-enhancing drugs for cancer patients. | VSTM competitors |
| Vir Biotechnology Inc (VIR) | Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. | VIR competitors |
| Corvus Pharmaceuticals Inc (CRVS) | Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. | CRVS competitors |
| Theravance Biopharma Inc (TBPH) | Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe... | |
| Nuvation Bio Inc (NUVB) | Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology. | NUVB competitors |
| Tyra Biosciences Inc (TYRA) | Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and improve outcomes... | TYRA competitors |
| Biohaven Ltd. (BHVN) | Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops candidate products targeting neurological diseases and rare disorders... | BHVN competitors |
| Beam Therapeutics Inc (BEAM) | Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. | BEAM competitors |
| Vera Therapeutics Inc (VERA) | Vera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immune diseases... | VERA competitors |
| DBV Technologies (DBVT) | DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products. | DBVT competitors |
| Inhibrx Biosciences, Inc. (INBX) | Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates. | INBX competitors |
| Zenas BioPharma, Inc. Common Stock (ZBIO) | Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based... | ZBIO competitors |
Frequently Asked Questions About VOR
Who are Vor Biopharma's main competitors?
The companies most similar to Vor Biopharma include Verastem (VSTM), Vir Biotechnology (VIR), Corvus Pharmaceuticals (CRVS), Theravance Biopharma (TBPH) and Nuvation Bio (NUVB), listed from the closest match.
Who is Vor Biopharma's biggest competitor?
Beam Therapeutics (BEAM) is the largest of the similar companies at $2.36B; Verastem (VSTM) is the closest match by business profile, size, sector and industry.
How does VOR stock compare with its competitors?
VOR's net margin is 0.0% against a peer median of 0.0%.
Which of Vor Biopharma's competitors pays a higher dividend?
Vor Biopharma pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Vor Biopharma bigger than its competitors?
No. Vor Biopharma is 9th by market cap among the 13 companies on this page; the largest is Beam Therapeutics (BEAM) at $2.36B.
VOR pages: Overview, Earnings, Forecast, Financials, Competitors